[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cystic Fibrosis Therapeutics Market Value Stood at USD 1.94 Bn in 2016, States RNCOS in Its New Report Available at MarketPublishers.com

31 Jul 2017 • by Natalie Aster

LONDON – Worldwide, the cystic fibrosis (CF) therapeutics industry has seen considerable growth in the recent past, and is creating a host of opportunities to the various industry players. With increasing life expectancy and surging awareness, the global cystic fibrosis therapeutics market is expected to reach newer acmes. Also, there exists a huge opportunity for market participants to tap the rapidly developing market, which would collect huge revenue owing to the increasing strategic consolidations and commercialisation of the novel drugs targeting the CF transmembrane conductance regulator (CFTR) gene or protein.

The value of the CF therapeutics market stood at USD 1.94 billion as of 2016. CFTR modulators accounted for the lion’s revenue share in the industry, which was due to recent market approvals of Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) to treat patients having CF, and strong pipeline. CFTR mutation class II captured the largest share of the overall market in 2016. The small molecule segment grabbed the largest slice in the entire CF therapeutics market pie as of 2016.

North America captures the biggest market share, which is owing to the growing awareness, in tandem with the rise of research incentives. Meantime, the market of Europe is set to record the most rapid growth due to the regional players’ increasing focus on the issue.

New research report “Global Cystic Fibrosis Therapeutics Market Outlook 2022” drawn up by RNCOS E-Services gives a deep, unbiased analysis of the CF therapeutics market globally focusing on key regions like North America, Europe, and APAC. It features detailed market segmentation based on mutation class, pharmacological class, type of drug molecule, and geography-wise penetration.

The study offers deep insights into the current market situation, alongside forecasting the reviewed segments though to 2022. The report provides an all-round analysis of all the main market segments; tracks key market trends and developments; reviews major marketed products; includes a CF pipeline analysis; offers detailed Porter's five forces analysis. The report presents granular profiles of the 10 leading players with the key financials, providing an exhaustive outlook of the world CF therapeutics industry. Additionally, the research elucidates major company developments pertaining to the CF industry.

For more comprehensive reports by RNCOS E-Services, please, visit the publisher's page at MarketPublishers.com.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]

Analytics & News

Weekly Digest